Vanguard Capital Management
CGTX icon

Vanguard Capital Management’s Cognition Therapeutics CGTX Stock Holding History

Vanguard Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.95M Buy
3,438,775
+436,988
+15% +$517K ﹤0.01% 3202
2026
Q1 		$2.28M Buy
+3,001,787
New +$3.49M ﹤0.01% 3318

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return

Vanguard Capital Management's CGTX Position: Q2 2026 in Review

Vanguard Capital Management increased its Cognition Therapeutics (CGTX) stake by 15% in Q2 2026, buying an estimated $517K and bringing the position to 3,438,775 shares worth $3.95M. The position accounts for ﹤0.01% of the portfolio, ranked #3202.

Vanguard Capital Management first reported a position in CGTX in Q1 2026 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Vanguard Capital Management held 3,438,775 shares of Cognition Therapeutics worth $3.95M as of Q2 2026.
  • Vanguard Capital Management bought 436,988 Cognition Therapeutics shares in Q2 2026, an estimated $517K.
  • Cognition Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3202 holding.
  • Vanguard Capital Management first reported a position in Cognition Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.